BioCryst Pharmaceuticals (BCRX) pipeline and stated timing

Name in SEC filings: BIOCRYST PHARMACEUTICALS INC

Pipeline at a glance

Program	Event	Stage	Stated timing	Filing
BCX17725	/data readout	Stage not stated	end of 2026	8-K · Aug 5, 2026

Source: ORION, orionbiotechai.com/company/BCRX, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/BCRX

Nearest upcoming stated timing: BCX17725 · Topline/data readout · end of 2026

SEC sources last checked Oct 18, 2026.

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

BCX17725

Matched

Topline/data readoutend of 2026

Stage: Not stated

Public float: $1,863,392,680 · as of Jun 30, 2025 · SEC filing

expects to report data from this part by the end of 2026.

8-K · Filed Aug 5, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001171843-26-005223

Alert me · Calendar: same stage and window-end month (2026-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of Oct 19, 2026.

Program / event	Stated period and SEC wording	Disclosure in stated period
BCX17725Clinical results	end of 2026 “expects to report data from this part by the end of 2026.” Filed Aug 5, 2026 · EX-99.1	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
BCX17725Clinical results	year-end 2026 “Dosing is ongoing in the Phase 1 Part 4 study in up to 12 patients, with proof-of-concept data expected by year-end 2026.” Filed Jun 29, 2026 · EX-99.1	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
BCX17725Clinical results	end of 2026 “The company has begun dosing in Part 4 of this trial, which will enroll up to 12 patients for three months, and expects to report data from this part by the end of 2026.” Filed May 6, 2026 · EX-99.1	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
BCX17725Clinical results	end of 2026 “we expect to report data from the clinical trial of BCX17725 for the treatment of Netherton syndrome in up to 12 patients by the end of 2026.” Filed Feb 26, 2026 · 10-K	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch BCRX

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for BCRX. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window: The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date: The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q: First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original: The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status: One of seven labels set by founder review of the original filings. Definitions: Methodology.

See BCRX in the calendar · Review labels and methodology